title: Management of lung cancer-associated anaemia: the Spanish Lung Cancer Anaemia Survey (SLCAS).
abstract: BACKGROUND
  The purpose of the Spanish Lung Cancer Anaemia Survey (SLCAS) was to thoroughly investigate lung cancer-associated anaemia management, and describe the profile of lung cancer patients in relation to anaemia incidence and tumour type in Spain.
  
  
  METHODS
  This survey collected data from 1089 randomly recruited patients gathered by 50 Spanish physicians at 38 sites. In addition, a qualitative assay was performed through 16 one-to-one and 2 one-to-two interviews, and a discussion group of 4 cancer specialists participating in the survey.
  
  
  RESULTS
  Lung cancer patients undergoing chemotherapy treatment had haemoglobin (Hb) levels <12.0 g/dl in 58.0% of the cases, in contrast to 39.0% of patients receiving no chemotherapy. Anaemia was treated in 53.0% of patients with Hb<12 g/dl (45.0% epoetin, 3.9% transfusion, 4.1% iron). Mean Hb level trigger was 9.7 g/dl for administration of epoetin and 8.2 g/dl for blood transfusion.
  
  
  CONCLUSIONS
  SLCAS reveals a significant change in the management of anaemia and clinical practice pattern in the use of erythropoiesis-stimulating agents (45.0% vs. 18.0%) and much less use of blood transfusions (3.9% vs. 15.0%) since the European Cancer Anaemia Survey performed five years ago.
authors: Hospital Clínic, Department of Medical Oncology, Barcelona, Spain. gascon@clinic.ub.es
authors: Pere
authors: P
authors: Gascón
authors: José
authors: J
authors: Almenárez
authors: Ángel
authors: Á
authors: Artal
authors: Carlos
authors: C
authors: Camps
authors: José Luis
authors: JL
authors: Fírvida
authors: Pilar
authors: P
authors: Garrido
authors: José Luis
authors: JL
authors: González Larriba
authors: Joaquín
authors: J
authors: Montalar
references: Am J Clin Oncol. 1982 Dec;5(6):649-55
references: 7165009
references: Cancer. 2001 Jun 15;91(12):2214-21
references: 11413508
references: Support Care Cancer. 2007 Mar;15(3):265-72
references: 17120069
references: Eur J Cancer. 2009 Jan;45(1):8-11
references: 19058959
references: Crit Rev Oncol Hematol. 2003 Jul;47(1):1-11
references: 12853095
references: Lung Cancer. 2005 Dec;50(3):401-12
references: 16191450
references: Anticancer Res. 2007 Jul-Aug;27(4A):1745-57
references: 17649769
references: Oncology. 2005;68 Suppl 1:3-11
references: 15855811
references: JAMA. 2008 Feb 27;299(8):914-24
references: 18314434
references: Lancet. 2009 May 2;373(9674):1532-42
references: 19410717
references: Blood. 2010 Nov 18;116(20):4045-59
references: 20974674
references: J Thorac Oncol. 2006 Sep;1(7):716-25
references: 17409943
references: Cochrane Database Syst Rev. 2009 Jul 08;(3):CD007303
references: 19588423
references: Eur J Cancer. 2004 Oct;40(15):2293-306
references: 15454256
references: Lung Cancer. 2007 Oct;58(1):104-11
references: 17601632
references: J Natl Cancer Inst. 1999 Oct 6;91(19):1616-34
references: 10511589
references: Oncologist. 2008;13 Suppl 3:4-10
references: 18458118
references: Lung Cancer. 2008 Feb;59(2):211-8
references: 17875340
references: N Engl J Med. 2007 Jun 14;356(24):2445-8
references: 17568023
references: Oncology. 2006;70(1):34-48
references: 16493206
references: Eur J Cancer. 2007 Jan;43(2):258-70
references: 17182241
references: Clin Lab Haematol. 2005 Feb;27(1):1-13
references: 15686502